Company intelligence / Profile preview

ProSyntest

Grabels, Occitanie, France

Ownership: Private
Employees: ~18
Development stage: Other

Overview

ProSyntest was a French biotechnology company specializing in medicinal chemistry and drug discovery services. Founded in 2004 and headquartered in Montpellier, the company focused on the design and synthesis of diverse small molecule libraries and provided hit-to-lead optimization for pharmaceutical and biotech partners. In addition to its service offerings, ProSyntest maintained internal research programs targeting oncology and inflammatory diseases. The company was acquired by Galapagos NV in July 2010, at which point its operations were integrated into Galapagos' service division, BioFocus.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

GalapagosBioFocus

Beyond the preview

Go deeper on ProSyntest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProSyntest.

Explore the full profile